Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE: TEVA) and Royalty Pharma (Nasdaq: RPRX) agreed on up to $500 million to accelerate development of Teva’s anti-IL-15 antibody TEV-’408, including $75 million to co-fund a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option for an additional $425 million to support Phase 3 if Phase 2b results warrant. TEV-’408 is in Phase 1b for vitiligo and Phase 2a for celiac disease. If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales.
Teva (NYSE: TEVA) announced that Richard Francis, Teva president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
The presentation starts at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). A live webcast will be available on Teva’s investor relations website and an archived recording will be posted within 24 hours and remain accessible for up to 30 days.
Teva (NYSE: TEVA) received a ratings upgrade and outlook revisions on Dec 24, 2025: S&P raised the long-term rating to BB+ (from BB) with a stable outlook, while Moody's affirmed B1a and moved the outlook to positive from stable.
S&P cited adjusted leverage of 4.4x as of Sept 30, 2025 and expects leverage to drop below 4.25x in coming quarters; Moody's expects leverage toward 3.5x within 12–18 months. Both agencies pointed to deleveraging, returning revenue growth, branded-medicine momentum, biosimilar launches, and strong liquidity as drivers supporting higher ratings.
Alvotech (NASDAQ: ALVO) and Teva (NYSE: TEVA) announced a settlement and license with Regeneron that sets a U.S. market entry date for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), in the fourth quarter of 2026, or earlier under specified circumstances, subject to FDA approval.
AVT06 has already received marketing approvals in the United Kingdom, Japan, and the 30 EEA countries. A January 2024 confirmatory study met its primary endpoint, showing high similarity to Eylea® for neovascular AMD.
Teva (NYSE:TEVA) will release its fourth quarter 2025 financial results on Wednesday, January 28, 2026 at 7:00 a.m. ET.
Teva will host a conference call and live webcast the same day at 8:00 a.m. ET. Investors must register in advance to obtain local or toll-free dial-in numbers and a personal PIN. A live webcast will be available at https://ir.tevapharm.com/Events-and-Presentations, and a replay will be posted within 24 hours on the same site.
Teva (NYSE: TEVA) posted its Q4 2025 Aide Memoire on the company's Investors page to help investors ahead of fourth-quarter results.
The Aide Memoire compiles previously disclosed public information, prior results, management commentary and select independent data. Q4 2025 results are scheduled for Wednesday, January 28, 2026 at 7:00 AM ET, followed by a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) submitted a New Drug Application (NDA) to the FDA on December 9, 2025 for olanzapine extended-release injectable suspension (TEV-'749), an investigational once-monthly subcutaneous long-acting injectable (LAI) for adults with schizophrenia.
The NDA is supported by Phase 3 SOLARIS trial data, including Week 56 results that the company says met efficacy and safety endpoints and showed a profile consistent with oral olanzapine. The formulation uses SteadyTeq copolymer technology, proprietary to Medincell. Olanzapine LAI is not approved by any regulatory authority at this time.
Teva (NYSE: TEVA) announced that the European Commission granted marketing authorizations on Nov 25, 2025 for two denosumab biosimilars: PONLIMSI (biosimilar to Prolia) and DEGEVMA (biosimilar to Xgeva).
The approvals follow positive CHMP opinions and allow Teva to launch both products in key European markets in the coming months. Teva frames the authorizations as a milestone for its biosimilars portfolio and part of its Pivot to Growth strategy to broaden patient access to bone‑health biologics across Europe.
Teva (NYSE: TEVA) announced that Richard Francis, president and CEO, and other executive management will present at three investor conferences in early December 2025.
Schedule: Evercore Healthcare Conference on Dec 3, 2025 at 8:20 AM ET; Piper Sandler Healthcare Conference on Dec 3, 2025 at 11:00 AM ET; and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 AM ET. Live webcasts will be available via Teva’s Investor Relations website and archived within 24 hours after each live presentation.
Teva (NYSE:TEVA) launched Teva Rise, a global open innovation platform on Nov 19, 2025 to connect startups and tech companies with Teva business units across R&D, manufacturing, supply chain and commercial functions.
The program issues an open call for solutions to seven real-world challenges (human-predictive platforms, AI clinical-trial protocol design, long-acting injectable patient experience, tender value optimization, asset predictive maintenance, product quality & risk prediction, and resource allocation intelligence) and may pilot selected startups across Teva’s global ecosystem.
Teva said it will channel tens of millions of dollars into adopting these innovations as part of its Pivot to Growth strategy.